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e equal contribution
esponsibility of InstAbstract Biodegradable polyamines have long been studied as potential recombinant viral gene vectors.
Spermine (SPE) is an endogenous tetra-amine with excellent biocompatibility yet poor gene condensation
capacity. We have previously synthesized a polyspermine based on SPE and poly(ethylene glycol) (PEG)
diacrylate (SPE-alt-PEG) for enhanced transfection performance, but the synthesized SPE-alt-PEG still
lacked speciﬁcity towards cancer cells. In this study, folic acid (FA) was incorporated into SPE-alt-PEG to
fabricate a targeted gene delivery vector (FA-SPE-PEG) via an acylation reaction. FA-SPE-PEG exhibited
mild cytotoxicity in both cancer cells and normal cells. FA-SPE-PEG possessed higher transfection
efﬁciency than PEI 25 K and Lipofectamines 2000 in two tested cancer cell lines at functional weight
ratios, and its superiority over untargeted SPE-alt-PEG was prominent in cells with overexpressed folate
receptors (FRs). Moreover, in vivo delivery of green ﬂuorescent protein (GFP) with FA-SPE-PEG resulted
in highest ﬂuorescent signal intensity of all investigated groups. FA-SPE-PEG showed remarkably
enhanced speciﬁcity towards cancer cells both in vivo and in vitro due to the interaction between FA and
FRs. Taken together, FA-SPE-PEG was demonstrated to be a prospective targeted gene delivery vector
with high transfection capacity and excellent biocompatibility.
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Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND
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Gene therapy targeting lung cancer 3371. Introduction
Gene therapy has been investigated for decades as a therapeutic
approach for the treatment of various diseases related with
genetic disorders, including cancers1–4. The success of gene
therapy relies on the accurate delivery of the therapeutic gene to
tumor sites. The success of this approach necessitates of an
efﬁcient and safe gene vector5,6. Recombinant viral vectors
have been widely used for gene delivery due to the inherent
ability and relatively high transfection efﬁciency. However, the
inability to deliver large genes and the immunogenic properties
of these vectors remain to be addressed7–9. In contrast, non-viral
vectors have large delivery capacity, low immunogenicity, and
ﬂexible structures, making them excellent alternatives to viral
vectors2,4,10,11.
Cationic polymers manifest excellent ability to condense and
protect genes via electrostatic interactions. Polyethylenimine (PEI)
has become a gold standard of non-viral vectors because of its
high transfection efﬁciency in various cell lines12,13. However,
because of its high molecular weight, PEI shows severe cytotoxi-
city and poor biocompatibility, thereby limiting its clinical
application14,15. To resolve these obstacles, other biocompatible
polymers, especially endogenous polyamines, have been devel-
oped as non-viral vectors for the safe and efﬁcient delivery of
therapeutic genes16.
Spermine (SPE) is an endogenous tetra-amine participating in
eukaryotic cell metabolism17. Despite its prominent biocompat-
ibility, SPE exhibits poor transfection efﬁciency. The transfection
performance of SPE could be modiﬁed by crosslinking its primary
and secondary amine groups with acrylate or hydroxyl groups,
resulting in biodegradable polyspermines18–21. In our previous
study, we prepared a polyspermine based on SPE and poly
(ethylene glycol) (PEG) diacrylate (SPE-alt-PEG) for the aerosol
gene delivery20. SPE-alt-PEG was shown to be a safe and efﬁcient
gene vector for the lung cancer therapy, but a facilitated speciﬁcity
would be necessary for a better treatment outcome. To enhance
delivery speciﬁcity, it is essential to introduce a targeting ligand
onto SPE-alt-PEG. Folate receptor (FR) is abundantly expressed
on the membrane of epithelial carcinomas, yet FR expression on
normal cells is rather limited22,23. The interaction between folic
acid (FA) and FRs could not only lead to a better speciﬁcity, but
also reinforce the internalization rate. Therefore, we chose FA as a
targeting ligand for gene delivery and fabricated folate-conjugated
SPE-alt-PEG (FA-SPE-PEG).
FA-SPE-PEG was synthesized by an acylation reaction between
the carboxyl groups of FA and the amino groups of SPE-alt-PEG.
The physicochemical properties of FA-SPE-PEG and its complexes
with DNA were investigated, and the cytotoxicity of FA-SPE-PEG
was compared with SPE and PEI 25K in cancer cells as well as
normal cells. In addition, in vitro transfection efﬁciency as well as
targeting ability of FA-SPE-PEG was investigated in cells with or
without overexpressed FRs. Moreover, the in vivo transfection
efﬁciency was elucidated via a green ﬂuorescent protein (GFP)
expression assay in BALB/c mice. FA-SPE-PEG is an ester-based
polyamine which could be degraded by both acidic tumor micro-
environment and endogenous esterase. This biodegradability led to
mild cytotoxicity, low immunogenicity, and modiﬁed biocompat-
ibility7,24. The speciﬁc interaction between FA and FRs endowed FA-
SPE-PEG with excellent targeting capacity towards cancer cells,
further attenuating toxicity to normal cells. Altogether, it is evident toconsider FA-SPE-PEG as an efﬁcient and safe vector for targeted
gene delivery in tumor therapy.2. Materials and methods
2.1. Materials
PEG diacrylate, SPE, FA, anhydrous ethanol, and branched PEI
25K were purchased from Sigma (St. Louis, MO, USA). The
pGL3 vector (5.3 kb) with a luciferase gene driven by an SV40
promoter and enhancer, and the Cell Titer 96s Aqueous One
Solution Reagent were purchased from Promega (Madison, WI,
USA). pEGFP-N2 (4.7 kb) encoding a GFP and driven by an
immediate early promoter of CMV was purchased from Clontech
Laboratories (Palo Alto, CA, USA). The plasmids were propagated
in Escherichia coli, extracted by the alkaline lysis technique, and
puriﬁed using a QIAGEN kit (Chatsworth, CA, USA). All other
chemicals were of reagent grade.
2.2. Preparation and characterization of FA-SPE-PEG and
FA-SPE-PEG/DNA complexes
FA-SPE-PEG was synthesized by two separated steps (Fig. 1A).
Firstly, SPE-alt-PEG was synthesized by a previously reported
Michael addition reaction. The preparation details were demon-
strated in our former study20.
FA-SPE-PEG was prepared by coupling FA onto SPE-alt-PEG
via DCC/NHS (dicyclohexylcarbodiimide/N-hydroxysuccinimide)
chemistry according to a previous study25. Brieﬂy, 0.16 mmol FA
was dissolved in 3.0 mL anhydrous DMSO, and then activated by
DCC and NHS. The molar ratio of FA, DCC, and NHS was 1:2:2.
The mixture was stirred at room temperature for 18 h, and then
centrifuged to remove the byproduct, dicyclohexyl urea. SPE-alt-
PEG was then added to the reaction mixture of activated FA,
unreacted DCC and NHS. The reaction was continued at room
temperature for 6 h under nitrogen atmosphere. The crude product
was ﬁrst dialyzed (MWCO¼1000 Da) against DMSO for 3 days to
remove uncoupled FA, and thereafter against distilled water for
2 days. The synthesized FA-SPE-PEG was lyophilized and stored at
–20 1C. The composition of FA-SPE-PEG was conﬁrmed by
1H NMR.
All FA-SPE-PEG/DNA complexes were freshly prepared
before use. The DNA condensation and protection abilities of
FA-SPE-PEG were conﬁrmed by electrophoresis according to
Jiang et al.26. All the complexes were prepared by gently mixing
pDNA (pGL3-control, 0.1 μg) with equal volume of FA-SPE-PEG
solution at different N/P ratios, and the complexes were incubated
at room temperature for 30 min. To evaluate the DNA protection
and release abilities of FA-SPE-PEG, 1 μL of DNase I (2 U) or
phosphate-buffered saline (PBS) in DNase/Mg2þ digestion buffer
(50 mmol/L Tris–HCl, pH 7.6 and 10 mmol/L MgCl2) was added
to 4 μL complex solution (0.1 μg pDNA with 1.0 μg FA-SPE-
PEG) or to naked pDNA, the mixture was then incubated at 37 1C
with shaking at 100 rpm for 30 min. To inactivate DNase, all
samples were treated with 4 μL EDTA (250 mmol/L) for 10 min
and mixed with 1% sodium dodecyl sulfate (SDS, pH 7.2) to a
ﬁnal volume of 15 μL. The samples were further incubated for 2 h,
and the electrophoresis was performed in 1% agarose gel with
Tris-acetate-EDTA running buffer at 50 V for 1 h.
Figure 1 Synthesis and the composition conﬁrmation of FA-SPE-PEG. (A) Proposed reaction scheme for FA-SPE-PEG. (B) Representative
1H NMR spectrum of FA-SPE-PEG in D2O: (a) δ 1.6 and (b) δ 1.8 ppm (–CH2–, SPE); (c) δ 2.7–3.2 ppm (–NH–CH2–, SPE); δ 4.1–4.3 ppm
(–CH2–, PEG); (*) δ 7.8 ppm (methylene, FA).
Mei Zhang et al.338The morphologies of the FA-SPE-PEG/DNA complexes were
observed by EF-TEM (LIBRA 120, Carl Zeiss, Germany). The
average particle size and surface charge of the complexes were
determined by dynamic light scattering (DLS) spectrophotometer
(ELS8000, Otsuka Electronics, Osaka, Japan) at 901 and 201,
respectively.
2.3. Cell culture, cell viability and transfection efﬁciency in vitro
A549 (human lung carcinoma, ATCC, Manassas, VA, USA) cells,
KB (human epidermal carcinoma, Korean Cell Line Bank, Seoul,
South Korea) cells, KB cells with overexpressed folate receptors
(KB/F cells), and 16HBE (immortalized human bronchial epithelial)
cells were incubated in RPMI 1640 (Gibco BRL, Paris, France),
supplemented with 10% fetal bovine serum (HyClone, Logan, UT),
streptomycin at 100 μg/mL, and penicillin at 100 U/mL. All the
cells were incubated at 37 1C in humidiﬁed 5% CO2 atmosphere.
The in vitro cytotoxicity FA-SPE-PEG was evaluated by Cell
Titer 96s Aqueous One Solution Proliferation Assay (MTS assay,
Promega, Madison, WI, USA) according to a previously reported
method26. Brieﬂy, A549 and 16HBE cells were seeded into 96-
well plates at an initial density of 1 104 cells/well in 0.2 mL
growth media. After incubation for 18 h, the growth media were
replaced with serum-free media containing FA-SPE-PEG of
different concentrations. Cells treated without FA-SPE-PEG were
used as a control group, and cells treated with PEI 25 K and SPE
were used as parallel control groups. After incubation for another
24 or 72 h, the media was changed for growth media containing
20 μL Cell Titer 96s Aqueous One Solution Reagent. The cells
were further incubated for 3 h, and the absorbance at 570 nm was
measured with an ELISA plate reader (GLR 1000, Genelabs
Diagnostics, Singapore) to represent the viability of the cells.
The in vitro transfection efﬁciency and the targeting capacity of
FA-SPE-PEG were evaluated by luciferase assay (Promega,
Madison, WI, USA). Brieﬂy, A549 and KB/F cells were seeded
into 24-well plates at an initial density of 1.5 105 cells/well.
After incubation for 18 h, the media were changed for serum-freegrowth media containing FA-SPE-PEG/pGL3 (1 μg pGL3) or
SPE/pGL3 complexes at different weight ratios. Cells treated with
naked pGL3, SPE-alt-PEG/pGL3, PEI 25 K/pGL3 and
Lipofectamines 2000/pGL3 were used as control groups. After
transfection for 4 h, the media were replaced with fresh growth
media containing 10% serum and the cells were incubated for 24 h
at 37 1C. The luciferase assay was conducted according to the
manufacturer's protocol.
To investigate the buffering capacity of FA-SPE-PEG, cells
were treated with 200 nmol/L baﬁlomycin A1 for 10 min before
the assay. Then the transfection efﬁciency was evaluated as
described above. To assess the targeting ability of FA-SPE-PEG,
luciferase assay described above was carried out in KB cells and
KB/F cells.
The superiority of FA-SPE-PEG as an efﬁcient gene vector was
further evaluated by GFP expression assay. Brieﬂy, KB/F cells
were seeded into confocal dishes at a primary density of
1 105 cells/dish in 1.5 mL growth media. After incubation for
18 h, cells were treated with serum-free media containing FA-SPE-
PEG/GFP (1 μg GFP) or PEI 25 K/GFP complexes at functional
weight ratio. Cells treated with only serum-free media were set as
a control. After incubation for 4 h, the media were changed with
fresh growth media containing 10% serum and the cells were
incubated for 24 h at 37 1C. After washing with PBS for 3 times,
cells were ﬁxed with 4% formaldehyde for 20 min and dyed with
DAPI for another 20 min. Thereafter, cells were washed with PBS
for 3 times and rinsed with 1 mL PBS-glycerin buffer (50%, v/v).
The synthesized samples were directly observed using a confocal
laser scanning microscope (CLSM, MRC-1024, Bio-Rad, UK).
Composite images were made by overlapping the images of the
individual channels.
2.4. Transfection efﬁciency study in vivo
All animal experiments were conducted under protocols approved
by the Guidelines for the Care and Use of Laboratory Animals of
China Pharmaceutical University. Six-week-old female BALB/c
Gene therapy targeting lung cancer 339mice (Breeding and Research Center, Seoul National University,
Korea) were kept with temperature and relative humidity of
2372 1C and 50720%, respectively, in a 12 h light–dark cycle.
The mice were placed in a nose-only exposure chamber for the
aerosol delivery of FA-SPE-PEG/GFP complexes. Mice treated
with PBS were used as a blank control, and mice treated with
naked GFP or PEI 25 K/GFP complexes were used as parallel
control groups. All mice were sacriﬁced 48 h after aerosol
delivery, and the lungs were collected for GFP analysis. The
lungs were ﬁxed in 4% paraformaldehyde at room temperature and
embedded in Tissue-Tek OCT (Sakura, Torrance, CA, USA).
Lung cryosections (10 μm) were prepared by a microtome (Leica,
Nussloch, Germany) and the GFP signal was detected by a Zeiss
LSM510 confocal microscope (Carl Zeiss, USA).2.5. Statistical analysis
All data were presented as mean values7standard deviation. The
unpaired t-test was used to determine the statistical signiﬁcance of
differences among groups. Po0.05 was considered as signiﬁcant.Figure 2 Characterization of FA-SPE-PEG/pDNA complexes. (A) A
complexes at various weight ratios. The complexes were loaded onto 1%
(TAE) buffer at 100 V for 40 min. (B) Protection and release assay of DNA
buffer for 1 h at 50 V. (C) EF-TEM images of FA-SPE-PEG/pDNA comp
distribution assay. (E) Particle surface charges of FA-SPE-PEG/pDNA at3. Results and discussion
We described the synthesis of SPE-alt-PEG in our previous
study20. SPE-alt-PEG is a hydrophilic ester-based polyspermine
with a molecular weight of 5.76 kDa and a polydispersity index of
1.13. The chemical composition of the product was conﬁrmed by
1H NMR. In the present study, we introduced a targeting ligand,
FA, into SPE-alt-PEG, for a better targeting capacity towards
cancer cells overexpressing folate receptors.3.1. Preparation and characterization of FA-SPE-PEG and FA-
SPE-PEG/DNA complexes
FA-SPE-PEG was synthesized via the amide linkage between the
carboxyl group of FA and the amino groups of SPE-alt-PEG.
Consistent with our former study, 1H NMR analysis showed proton
peaks of SPE (–CH2–) at δ 1.6–1.8 ppm and the peaks of PEG
diacrylate (–CH2–) at δ 4.1–4.3 ppm, indicating the successful
synthesis of SPE-alt-PEG (Fig. 1B). In addition, proton peaks at
δ 7.8–7.9 ppm in the 1H NMR spectra belonged to the methylenegarose gel electrophoresis of FA-SPE-PEG/pDNA (pGL3-control)
agarose gel with EtBr (0.1 μg/mL) and run with Tris–acetate EDTA
. Electrophoresis was performed in 1% agarose gel with TAE running
lexes at functional weight ratio (scale bar: 200 nm). (D) Particle size
functional weight ratio.
Figure 3 Cytotoxicity of FA-SPE-PEG at various concentrations in different cell lines: (A) 24 h cytotoxicity in A549 cells; (B) 72 h cytotoxicity
in A549 cells; (C) 24 h cytotoxicity in 16HBE cells; (D) 72 h cytotoxicity in 16HBE cells (mean7SD, n¼3).
Mei Zhang et al.340groups of FA, further conﬁrming the identity of FA-SPE-PEG. The
content of coupled FA was 4.3% (mol/mol), calculated by assign-
ing the protons of methylene groups at δ 4.6 ppm.
One major prerequisite for an efﬁcient gene vector lies in a high
gene afﬁnity. The gene condensation ability of FA-SPE-PEG was
assessed by agarose gel electrophoresis. Fig. 2A shows that FA-SPE-
PEG has clear condensation ability towards DNA at a weight ratio of
5, and that complete retardation of DNA migration was observed
when the weight ratio reached 10. Since efﬁcient gene delivery also
calls for protection of DNA from degradation, we evaluated whether
FA-SPE-PEG could protect DNA against nucleases. As shown in
Fig. 2B, DNA condensation by FA-SPE-PEG was effectively
protected upon the addition of nuclease compared to naked DNA.
SPE possesses poor gene afﬁnity despite high content of primary and
secondary amine groups, which is reported due to its relatively low
molecular weight. For better gene afﬁnity and targeting ability, we
crosslinked SPE with PEG and FA. Both the higher molecular weight
and abundant amine groups of FA-SPE-PEG contributed to its
facilitated gene afﬁnity and protective ability17,26,27. Moreover, the
ester bonds in FA-SPE-PEG could be easily degraded by esterase,
which further guaranteed its potential as a valid vector for the efﬁcient
and safe delivery of gene.
It is reported that the enhanced permeability and retention
(EPR) effect is a major mechanism involved in the targeting
delivery of nanoparticles, which makes physical properties such as
particle size and surface potential important factors in the assess-
ment of gene vectors19,26. As shown in Fig. 2C and D, FA-SPE-
PEG/DNA complexes were uniform spheres with an average
diameter of 56.0711.3 nm as determined by energy-ﬁltered
(EF)-TEM-TEM. FA-SPE-PEG/DNA complexes were slightly
positive-charged according to the DLS results in Fig. 2E. Positive
surface potential contributed to higher cellular uptake throughelectrostatic interactions between nanoparticles and negatively
charged cell membrane. Furthermore, the relatively low surface
charges (compared to other commonly used cationic vectors) also
led to better stability and less cytotoxicity, both of which further
validate the safety of FA-SPE-PEG as a gene vector28.3.2. Cell viability and transfection efﬁciency studies in vitro
Safety issues of non-viral gene vectors have remained a signiﬁcant
challenge to be addressed in clinical application. High positive
charges not only brought about excellent capacity to condense and
protect genes, but also led to severe cytotoxicity29–31. We have
previously showed SPE-alt-PEG to be a biocompatible gene vector
with low cytotoxicity at functional concentrations. In this study,
we investigated whether FA-SPE-PEG was as biocompatible as
SPE-alt-PEG. Results of MTS assay indicated that FA-SPE-PEG
exhibited similar cytotoxicity to that of SPE, both of which were
remarkably lower than the cytotoxicity of PEI 25 K. As shown in
Fig. 3, cells treated with FA-SPE-PEG manifested relatively high
viability even at the highest administrated concentration
(125 μg/mL) after incubation for different periods of time (viabi-
lity of A549 cells: 76.95% for 24 h and 73.56% for 72 h; viability
of 16HBE cells: 70.62% for 24 h and 70.97% for 72 h). On the
contrary, cells treated with PEI 25 K showed drastically decreased
viability even at low concentrations. The mild cytotoxicity of FA-
SPE-PEG was mainly assigned to the endogenous SPE and the
biodegradable ester bond. Furthermore, PEG also partially
shielded the excessive positive charges, avoiding the most severe
cellular damage17,27. These results strongly suggest that FA-SPE-
PEG can serve as a biocompatible gene vector.
Gene therapy targeting lung cancer 341Luciferase assays were carried out in KB/F cells (FR-over-
expressed), KB cells, and A549 cells to investigate the in vitro
transfection efﬁciency and targeting ability of FA-SPE-PEG. As
shown in Fig. 4A and B, the transfection efﬁciency of FA-SPE-
PEG was higher than SPE-alt-PEG, PEI 25 K and Lipofectamines
at all weight ratios in KB/F cells and A549 cells. Noteworthy, the
transfection efﬁciency of FA-SPE-PEG in KB/F cells was higher
than the untargeted SPE-alt-PEG when the weight ratio reached 10
(7.07 times higher at weight ratio of 10 and 4.35 times higher at
weight ratio of 20). Besides, the higher transfection efﬁciency of
FA-SPE-PEG in KB/F cells than that in KB cells further
reconﬁrmed the targeting capacity of FA-SPE-PEG towards FRs
(Fig. 4C). The speciﬁc interaction between FA and FRs facilitated
the internalization rate of gene complexes, which subsequently led
to higher transfection efﬁciency32–34. Apart from high entry rates
into cells, endosome escape also played a key role in the
transfection of gene. The buffering capacity of FA-SPE-PEG
was investigated to assess its endosome escape ability. Results
in Fig. 4D demonstrated that the transfection efﬁciency of FA-
SPE-PEG decreased sharply with the addition of baﬁlomycin A1
(a proton pump inhibitor), indicating that the proton sponge effectFigure 4 In vitro transfection efﬁciency and targeting ability studies of F
cells by FA-SPE-PEG/pGL3 at various weight ratios (mean7SD, n¼3)
(mean7SD, n¼3). Baﬁlomycin A1 (200 nmol/L) diluted in DMSO we
was added into wells for 4 h. Then the cells were incubated in growth med
cells and KB cells (mean7SD, n¼3). (E) GFP expression after KB/F cel
Composite images were made by overlapping the images of the individuais very important in the transfection process35. The superiority of
FA-SPE-PEG for gene targeting delivery was also conﬁrmed
intuitively by the expression of GFP via CLSM (Fig. 4E). Higher
GFP signal intensity was observed in cells treated with FA-SPE-
PEG/GFP. Although GFP signal intensity could also be observed
in cells treated with PEI 25 K, cells in this group exhibited severe
morphological changes. Taken with the results of in vitro cyto-
toxicity study, these results suggest that FA-SPE-PEG could serve
as a safe and efﬁcient non-viral vector for the targeting delivery
of genes.3.3. Transfection efﬁciency study in vivo
Based on the results of in vitro studies above, the targeted gene
delivery capacity of FA-SPE-PEG was reconﬁrmed in vivo via an
aerosol delivery approach. Gene delivery through the aerosol
approach remains a potential method for gene therapy of lung
cancer, which presents a non-invasive and instant access to
lungs18,20,27. After aerosol delivery of PBS, naked GFP, FA-
SPE-PEG/GFP complexes, and PEI 25K/GFP complexes, theA-SPE-PEG. Transfection efﬁciency in (A) KB/F cells and (B) A549
. (C) Buffering capacity study of FA-SPE-PEG/pGL3 in KB/F cells
re put into wells. After incubation for 10 min, transfection solution
ium for 24 h. (D) Targeting capacity of FA-SPE-PEG/pGL3 in KB/F
ls were treated with FA-SPE-PEG/GFP and PEI 25K/GFP complexes.
l channels.
Figure 5 In vivo transfection study after aerosol administration.
Observation of the GFP expression level after aerosol delivery of FA-
SPE-PEG/GFP complexes at a functional weight ratio to BALB/c mice
(magniﬁcation: 200 , scale bar: 100 μm).
Mei Zhang et al.342ﬂuorescent signal intensity of GFP was detected to represent the
transfection efﬁciency in vivo. It could be observed in Fig. 5 that
the GFP signal was most dominant in FA-SPE-PEG/GFP treated
group, consistent with the results of in vitro transfection studies.
The higher signal intensity of GFP validated that FA-SPE-PEG
showed enhanced transfection vs. PEI 25K as a targeting gene
delivery vector. In addition, the lack of obvious lesions in tissues
further conﬁrmed the excellent biocompatibility of FA-SPE-PEG
for in vivo gene delivery. We previously showed the in vivo tumor-
inhibiting effects of gene therapy in lung cancer using non-
targeting SPE-alt-PEG20, so it is rational to deduce that FA-
SPE-PEG would act as a valid vector for the targeting delivery of
therapeutic genes. The excellent biocompatibility and high trans-
fection efﬁciency of FA-SPE-PEG in vitro and in vivo strongly
suggest this ligand to be an important prospective targeting vector
for the gene therapy of cancer.4. Conclusions
In this study, we successfully synthesized a novel FR-targeted,
ester-based polyspermine, FA-SPE-PEG, and evaluated its poten-
tial as a vector for the targeted delivery of therapeutic genes. FA-
SPE-PEG possessed prominent capacities to condense DNA as
well as to protect DNA from the degradation by nucleases. FA-
SPE-PEG/DNA complexes exhibited appropriate physicochemical
properties for gene targeting delivery. The mild cytotoxicity and
favorable transfection efﬁciency of FA-SPE-PEG insured its
prospects as a valid gene vector. Moreover, results from transfec-
tion efﬁciency studies in vitro and in vivo validated that FA-SPE-
PEG manifested high speciﬁcity towards FR-overexpressed tumor
cells, which further enhance the potential of FA-SPE-PEG for the
targeted delivery of therapeutic genes. Altogether, FA-SPE-PEGnot only facilitated the cellular uptake of therapeutic genes, but
also showed strongly reduced toxicity towards normal tissues
when compared with other cationic gene vectors. In conclusion,
FA-SPE-PEG holds the prospects to serve as a biocompatible and
efﬁcient vector for targeted gene delivery in tumor therapy.
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